These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Predictors of acute scaffold recoil after implantation of the everolimus-eluting bioresorbable scaffold: an optical coherence tomography assessment in native coronary arteries. Sato T; Jose J; El-Mawardy M; Sulimov DS; Tölg R; Richardt G; Abdel-Wahab M Int J Cardiovasc Imaging; 2017 Feb; 33(2):145-152. PubMed ID: 27761749 [TBL] [Abstract][Full Text] [Related]
23. Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison. Kugler C; Markovic S; Rottbauer W; Wöhrle J Coron Artery Dis; 2017 Mar; 28(2):120-125. PubMed ID: 27845998 [TBL] [Abstract][Full Text] [Related]
24. Very late bioresorbable vascular scaffold thrombosis: a new clinical entity. Azzalini L; Al-Hawwas M; L'Allier PL EuroIntervention; 2015 May; 11(1):e1-2. PubMed ID: 25982486 [No Abstract] [Full Text] [Related]
25. Fate of side-branch jailing and a malapposed platinum marker after resorption of an everolimus-eluting bioresorbable vascular scaffold: serial optical coherence tomography observations. Karanasos A; Garcia-Garcia HM; van Geuns RJ; Regar E JACC Cardiovasc Interv; 2015 Mar; 8(3):e53-e54. PubMed ID: 25790767 [No Abstract] [Full Text] [Related]
26. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924 [TBL] [Abstract][Full Text] [Related]
27. A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting. Sato K; Latib A; Panoulas VF; Naganuma T; Miyazaki T; Colombo A JACC Cardiovasc Interv; 2014 Aug; 7(8):e103-4. PubMed ID: 25086841 [No Abstract] [Full Text] [Related]
28. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study. Abizaid A; Carrié D; Frey N; Lutz M; Weber-Albers J; Dudek D; Chevalier B; Weng SC; Costa RA; Anderson J; Stone GW; JACC Cardiovasc Interv; 2017 Sep; 10(18):1832-1838. PubMed ID: 28935075 [TBL] [Abstract][Full Text] [Related]
29. Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R. Mehilli J; Achenbach S; Woehrle J; Baquet M; Riemer T; Muenzel T; Nef H; Naber C; Richardt G; Zahn R; Gori T; Neumann T; Kastner J; Schmermund A; Hamm C EuroIntervention; 2017 Dec; 13(11):1319-1326. PubMed ID: 28649953 [TBL] [Abstract][Full Text] [Related]
31. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW; JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836 [TBL] [Abstract][Full Text] [Related]
32. Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis? Ishida K; Giacchi G; Brugaletta S; García-Álvarez A; Sabaté M Cardiovasc Revasc Med; 2016 Dec; 17(8):571-573. PubMed ID: 27345841 [TBL] [Abstract][Full Text] [Related]
33. Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy. Balbi M; Fedele M; Bezante GP; Brunelli C; Barsotti A J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):839-42. PubMed ID: 20216229 [No Abstract] [Full Text] [Related]
34. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial). Chevalier B; Cequier A; Dudek D; Haude M; Carrie D; Sabaté M; Windecker S; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Onuma Y; Serruys PW EuroIntervention; 2018 Jan; 13(13):1561-1564. PubMed ID: 29094677 [No Abstract] [Full Text] [Related]
35. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent. Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486 [TBL] [Abstract][Full Text] [Related]